Cooley advised HAYA Therapeutics, a biotechnology company pioneering precision RNA-guided regulatory genome-targeting therapeutics, on its $65 million Series A financing round. The round was led by Sofinnova Partners and Earlybird Venture Capital, with participation from Eli Lilly and Company, ATHOS, +ND Capital, Alexandria Venture Investments, and LifeLink Ventures, with additional support from existing investors Apollo Health Ventures, Longview Ventures (an affiliate of Broadview Ventures), 4see ventures, BERNINA Bioinvest and Schroders Capital.
Lawyers Danielle Gershowitz, Josh Seidenfeld, Amanda Gonzalez Burton, Kristine Kevorkova and Thomas Heiser led the Cooley team advising HAYA Therapeutics.
